茵陈五苓散加味联合更昔洛韦治疗婴儿胆汁淤积型巨细胞病毒肝炎疗效观察

Clinical Observation of Yinchen Wuling Powder (茵陈五苓散) Combined with Ganciclovir in Infant Cholestasis Cytomegalovirus Hepatitis

目的:评价茵陈五苓散加味联合更昔洛韦治疗婴儿胆汁淤积型巨细胞病毒肝炎的临床疗效。方法:将135例患儿随机分为对照组与治疗组,对照组66例给予保肝、维生素对症治疗,抗病毒给予更昔洛韦治疗,治疗组69例在对照组基础上加用茵陈五苓散加味治疗。对比分析两组患儿治疗前后临床症状改善时间、肝功能、肝脾大小、血CMV-DNA定量指标的改善情况及总有效率。结果:治疗组总有效率为92.8%,优于对照组的78.8%,差异有统计学意义(P<0.05)。与治疗前比较,治疗后两组在临床症状改善时间、肝功能指标、肝脾回缩指标均有所改善,治疗组均优于对照组(P<0.05)。治疗组血CMV-DNA下降与对照组比较差异无统计学意义。结论:茵陈五苓散加味治疗婴儿胆汁淤积型巨细胞病毒肝炎疗效显著。

Objective： This study aims to evaluate the clinical curative effect of Yinchen Wuling Powder combined with ganciclovir in the treatment of infant cholestatic cytomegalovirus hepatitis. Methods： A total of 135 patients were randomly divided into control group and treatment group, 66 cases of the control to liver-protective medicine, vitamin and ganciclovir, 69 cases of treatment group to Yinchen Wuling Powder modified treatment with liver-protective medicine, vitamin and ganciclovir. The improvement of total effective rate, improvement of clinical symptoms, liver function, liver and spleen size, and blood CMV-DNA quantification were investigated by comparing with the control groups. Results： The total effective rate was 92.8% in the treatment group and 78.8% in the control group, the difference of that was statistically significant（P〈0.05）. By comparing with the two groups of pre-treatment and after-treatment, the improvement of clinical symptoms, liver function index, liver and spleen retraction were observed and the treatment group was better than the control group（P〈0.05）. There was no significant difference in CMV-DNA between treatment group and control group. Conclusion：Yinchen Wuling powder is effective in the treatment of infants with cholestatic cytomegalovirus hepatitis.